Cognicept is a life sciences company dedicated to the treatment of
central nervous system (CNS) disorders
The focus of our company is the neurodegenerative condition of dementia, and in particular Alzheimer’s disease, the most common cause of dementia. Our mission is to find and develop novel treatments for Alzheimer’s disease that offer meaningful and lasting benefits to those afflicted with this condition. We aim to achieve our objective using a diversified business model, offering both entrepreneurial and consulting services. We seek to partner on opportunities where we can leverage our experience and contact network to expedite bringing new therapies to market in a cost effective manner. We are actively pursuing new methods of innovation and drug development, including open source development.
The World Health Organisation estimates that there are currently about 18 million people worldwide with Alzheimer’s disease. This figure is projected to nearly double by 2025 to 34 million. Alzheimer’s disease has a cascade effect in society, affecting not only the sufferer but also their partners, family, friends and carers. The economic cost of the condition represents both a major fiscal and social cost to society as a whole.
We invite you to contact us so that we can work together towards solutions for Alzheimer’s disease.
central nervous system (CNS) disorders
The focus of our company is the neurodegenerative condition of dementia, and in particular Alzheimer’s disease, the most common cause of dementia. Our mission is to find and develop novel treatments for Alzheimer’s disease that offer meaningful and lasting benefits to those afflicted with this condition. We aim to achieve our objective using a diversified business model, offering both entrepreneurial and consulting services. We seek to partner on opportunities where we can leverage our experience and contact network to expedite bringing new therapies to market in a cost effective manner. We are actively pursuing new methods of innovation and drug development, including open source development.
The World Health Organisation estimates that there are currently about 18 million people worldwide with Alzheimer’s disease. This figure is projected to nearly double by 2025 to 34 million. Alzheimer’s disease has a cascade effect in society, affecting not only the sufferer but also their partners, family, friends and carers. The economic cost of the condition represents both a major fiscal and social cost to society as a whole.
We invite you to contact us so that we can work together towards solutions for Alzheimer’s disease.